Krishna Institute of Medical Sciences Limited (KIMS) positions itself as a premier healthcare provider with a clear vision: to be the most preferred brand by delivering affordable care with superior clinical outcomes. The company's mission is rooted in a patient-centric approach, leveraging modern medical technology and fostering an environment of academic and research excellence for its medical professionals. This strategy aims to create value for a broad spectrum of stakeholders, including patients, doctors, employees, and investors.

The company was founded by Dr. B. Bhaskar Rao, a renowned cardio-thoracic surgeon with over 30,000 surgeries to his name. His entrepreneurial journey began with a 50-bed cardiovascular center focused on providing low-cost heart surgeries, a principle of affordable care that remains central to the KIMS ethos. Dr. Rao was also a key architect of the Rajiv Gandhi Aarogyasri scheme, a government health initiative for the underprivileged, which underscores his commitment to accessible healthcare.

Under the current leadership of CEO Dr. Abhinay Bollineni, who joined in 2013 and was appointed CEO in 2019, KIMS has continued its growth trajectory, culminating in a successful stock market listing in 2021. Dr. Bollineni emphasizes the integration of technology to enhance patient care and operational efficiency, such as using AI-driven tools for financial counseling.

KIMS operates a vast network of multi-specialty hospitals, providing comprehensive care across numerous disciplines including cardiac sciences, neurosciences, oncology, orthopedics, gastroenterology, and organ transplantation. The company has demonstrated a commitment to being at the forefront of medical innovation, adopting advanced technologies like the 4-Arm HD da Vinci Robotic Surgical System, Gamma Knife for non-invasive brain surgery, and the Mako Robotic system for knee replacements. This has enabled KIMS to achieve numerous clinical "firsts" in India and Asia.

From its beginnings with a single hospital in 2004, KIMS has expanded its footprint significantly across Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala. Its growth model is a hybrid of building wholly-owned facilities and entering into strategic partnerships with doctors, which fosters alignment and retains top clinical talent. This expansion has transformed KIMS from a regional leader into a national healthcare entity with a clear roadmap for future growth.

Official Website: https://www.kimshospitals.com/

• Revenue Performance: For Q3 FY26, operating revenue grew by a robust 29.2% year-over-year (YoY) to ₹9,977 million from ₹7,724 million in Q3 FY25. On a quarter-over-quarter (QoQ) basis, revenue increased by 3.9%. For the nine months (9M) of FY26, revenue was up 26.4% to ₹28,300 million.

• EBITDA Performance: Despite strong revenue growth, EBITDA for Q3 FY26 was flat YoY at ₹2,041 million compared to ₹2,050 million in Q3 FY25. The EBITDA margin contracted significantly to 20.4% in Q3 FY26 from 25.9% in the same quarter last year. The 9M FY26 EBITDA remained flat at ₹6,120 million.

• Profitability: Profit Before Tax (PBT) for Q3 FY26 saw a sharp decline of 49.0% YoY to ₹686 million. Similarly, Profit After Tax (PAT) fell by 43.9% YoY to ₹519 million. The PAT margin stood at 5.2% in Q3 FY26, a steep fall from 11.7% in Q3 FY25. The company notes that the decline in PBT is attributable to higher finance costs and depreciation, likely associated with its recent expansion activities.

• Earnings Per Share (EPS): Basic and Diluted EPS for Q3 FY26 was ₹1.3, down from ₹2.2 in Q3 FY25, reflecting the pressure on net profitability.

Summary: KIMS is demonstrating strong revenue growth driven by its expansion, but profitability is currently under significant pressure due to the higher costs associated with ramping up new hospital units.

• Affordable Quality Care Model: The company’s core philosophy, established by its founder, is to provide high-quality healthcare that is accessible and affordable, which helps drive patient volumes.

• Doctor Partnership Strategy: A significant portion of KIMS hospitals operate under a partnership model where doctors hold equity. This structure aligns the interests of the company with its top clinicians, fostering a sense of ownership, improving doctor retention, and promoting clinical excellence.

• Investment in Advanced Technology: KIMS has consistently invested in cutting-edge medical equipment, including the da Vinci Robotic System, Mako Robotics, Gamma Knife, and Tulsa-Pro System. This technological edge allows it to perform complex and minimally invasive procedures, attracting patients seeking advanced treatments.

• Proven Clinical Leadership: The company has a track record of achieving numerous medical "firsts" in India and Asia, such as the first COVID Double Lung transplant and the first Breathing Lung transplant. It is recognized as a number one player in several specialties, including organ transplantation and neurosurgery in Andhra Pradesh, according to a 2021 CRISIL report.

Summary: KIMS distinguishes itself through a unique combination of an affordable care model, an effective doctor-partnership strategy, and a commitment to investing in advanced medical technology to maintain clinical leadership.

• Historical Track Record: KIMS has a proven history of consistent and rapid growth. From 2005 to 2025, the company achieved a Compound Annual Growth Rate (CAGR) of 26.9% in total revenue and 29.7% in EBITDA.

• Geographic Expansion: The company has evolved from a regional leader concentrated in Telangana and Andhra Pradesh into a national player. It has aggressively expanded into Maharashtra, Karnataka, and Kerala, with plans for Tamil Nadu.

• Bed Capacity Expansion: The company is in a major expansion phase. Its total bed capacity is planned to exceed 9,100 beds. The immediate strategy involves adding over 2,000 beds through a mix of greenfield projects (new constructions), acquisitions, and Operations & Management (O&M) contracts.

• Inorganic Growth and Turnarounds: A key part of the strategy is acquiring and turning around other healthcare assets. The company notes that a recent acquisition was turned around from single-digit to double-digit EBITDA margins post-integration, demonstrating strong operational execution capabilities.

Summary: The company's growth is underpinned by a strong historical performance and is being accelerated by an aggressive, multi-state expansion strategy involving organic and inorganic routes to significantly increase bed capacity.

• New Market Penetration: The recent entry into Maharashtra, Karnataka, and Kerala presents a significant opportunity to capture market share in new, high-potential regions and replicate the success of its hub-and-spoke model.

• Operations & Management (O&M) Model: The O&M contracts in Guntur (Shikara and Chakra) and Sangli represent a capital-light expansion model. This allows KIMS to leverage its brand and operational expertise to generate revenue without the heavy upfront investment required for greenfield projects.

• Ramp-up of New Units: The newly opened or acquired hospitals in Thane, Nashik, Bengaluru, Kannur, and Kollam are in their initial ramp-up phase. As these facilities mature, increase patient volumes, and improve operational efficiencies, they are expected to contribute significantly to both revenue and profitability.

• Focus on High-End Specialties: The expansion of tertiary and quaternary care services, such as advanced organ transplants, robotic surgery, and comprehensive oncology centers in new locations (e.g., Nashik), provides an opportunity to attract higher-revenue patients and establish a reputation for clinical excellence in new markets.

Summary: KIMS has substantial growth opportunities driven by its entry into new geographic markets, the maturation of recently added facilities, and the expansion of high-margin, complex medical services.

• Bed Capacity: As of Q3 FY26, the total group bed capacity stands at 6,464, with 4,825 of those being operational beds. This is a significant increase from 4,859 beds in Q3 FY25, primarily due to new hospitals becoming operational.

• Occupancy Rate: The overall group occupancy rate was 49.0% in Q3 FY26. This represents a decline from 53.8% in Q3 FY25 and 53.5% in Q2 FY26. This dip is a direct result of the large number of new operational beds from recent expansions, which are still in the process of ramping up patient volumes.

• Regional Occupancy: The mature clusters show higher utilization. In Q3 FY26, Telangana and Andhra Pradesh reported occupancy rates of 51.6% each (down from 56.2% and 58.7% respectively in the prior quarter). In contrast, the newer units in Maharashtra (53.8%), Kerala (38.8%), and Karnataka (19.6%) reflect their early stages of operation.

• Capital Expenditure: While specific capex figures are not detailed, the company's roadmap indicates significant ongoing investment. Planned greenfield projects include a 550-bed hospital in Kondapur (Q1FY27), a 350-bed hospital in Rajahmundry (Q4FY27), and a 300-bed hospital in Chennai (Q4FY29), all of which will require substantial capital outlay.

Summary: The company has significantly increased its bed capacity, leading to a temporary dip in overall occupancy rates as new facilities ramp up; future growth is backed by a clear pipeline of capital-intensive projects.

• Greenfield Projects: KIMS has a clear pipeline for organic growth with several new hospitals planned:

• Kondapur II, Telangana: 550 beds, expected in Q1 FY27.

• Kompally (O&M), Telangana: 200 beds, expected in Q1 FY27.

• Anantapur II, Andhra Pradesh: 250 beds, expected in Q4 FY26.

• Ongole, Andhra Pradesh: 50 additional beds, expected in Q4 FY26.

• Rajahmundry II, Andhra Pradesh: 350 beds, expected in Q4 FY27.

• Thrissur (O&M), Kerala: 351 beds, expected in Q4 FY27.

• Chennai, Tamil Nadu: 300 beds, expected in Q4 FY29.

• Achieving Break-even in New Units: A primary focus is on ramping up operations at recently launched hospitals in Thane, Nashik, and Bengaluru to achieve break-even within the stated timelines (e.g., within 12 months for Thane and Mahadevapura).

• Strengthening Service Offerings: Plans include positioning new units as centers of excellence. For example, the Nashik unit is being developed into a high-end tertiary and transplant center for North Maharashtra, and the KIMS UAIMS unit is being developed as a flagship trauma care center.

• Accreditations: The company is actively pursuing NABH (National Accreditation Board for Hospitals & Healthcare Providers) accreditation for its new hospitals, a key benchmark for quality and patient safety that also facilitates empanelment with insurers and corporates.

Summary: KIMS has a well-defined and ambitious future plan focused on aggressive, multi-year capacity expansion through greenfield and O&M projects while simultaneously working to mature its newly operational hospitals.

• Group Margin Compression: The group's consolidated EBITDA margin has compressed to 20.4% in Q3 FY26 from 25.9% in Q3 FY25. This is a direct consequence of the operational costs and initial losses from the newly launched hospitals which are not yet profitable.

• Cluster-wise Profitability: The margin profile varies drastically between mature and new clusters. For 9M FY26:

• Telangana: The most profitable cluster, contributing 82.6% of the group's EBITDA with a strong margin of 30.4%.

• Andhra Pradesh: A mature and profitable cluster, contributing 27.9% of group EBITDA with a healthy margin of 24.5%.

• New Clusters: These are currently a drag on overall profitability. Maharashtra, Kerala, and Karnataka reported negative EBITDA contributions of -1.8%, -0.3%, and -8.4% respectively, as they are in the investment and ramp-up phase.

• Path to Margin Improvement: Margin recovery is contingent on the successful ramp-up of the new hospitals in Maharashtra, Kerala, and Karnataka. As these units increase occupancy and revenue, their operating leverage is expected to turn their EBITDA positive, which will lift the consolidated group margin.

Summary: Overall margins are currently diluted by investments in new, non-profitable hospital units, but the strong profitability of the company's mature clusters provides a stable base to support this expansion phase.

• Execution Risk: The company is undertaking a large-scale, multi-state expansion. The ability to successfully integrate acquisitions, complete greenfield projects on time and within budget, and ramp up operations at new hospitals is a significant execution risk.

• Margin Dilution: As demonstrated by the current financials, the initial phase of new hospitals is loss-making and puts considerable pressure on consolidated profitability and margins. A slower-than-expected ramp-up at these new units could prolong this period of margin dilution.

• Increased Debt and Finance Costs: The aggressive expansion is capital-intensive and is being funded by debt, leading to higher depreciation and finance costs. This is explicitly cited as the reason for the sharp drop in PBT and PAT and will continue to impact net profit until the new assets generate sufficient cash flow.

• Geographic Concentration: Despite national expansion, the Telangana cluster still accounts for 58.3% of total revenue and 82.6% of total EBITDA. Any adverse regulatory changes or increased competition in this core market could disproportionately affect the company's overall performance.

Summary: The primary risks are centered on the execution of its ambitious expansion strategy, which brings short-term financial pressure on margins and profitability and requires flawless operational management to succeed.

• Shareholding Structure: As of December 31, 2025, the promoter group holds 34.1% of the company. Institutional ownership is strong, with Domestic Institutional Investors (DII) at 33.2% and Foreign Institutional Investors (FII) at 16.1%. Key institutional shareholders include SBI MF, Axis MF, HDFC MF, and Nomura.

• Ramp-up Progress of New Units:

• Kerala (Kannur & Kollam): Kannur is now EBITDA positive. Both units are seeing progress through clinical expansion, facility modernization, and community outreach to drive volumes.

• Maharashtra (Nashik & Thane): Thane is showing strong revenue ramp-up, with losses narrowing significantly QoQ. Both units are focused on launching advanced specialties (ECMO, Transplants) and expanding their referral networks. Break-even for Thane is expected within 12 months.

• Karnataka (Bengaluru): The Mahadevapura unit has shown strong early traction, completing 16 organ transplants in Q3 FY26. It remains on track to achieve break-even within 12 months.

• O&M Units (Guntur & Sangli): Both units are EBITDA positive. Guntur has successfully transitioned to a full-time consultant model and is launching transplant programs. Sangli is being positioned as a regional hub for cancer care.

Summary: The company maintains a stable shareholding structure with strong institutional support, while its newest hospital units are showing tangible operational progress and are on a clear path toward profitability.